SCHEMBL7455338

SCHEMBL7455338

COc1cc2c(Nc3ccc(C)c(O)c3)ncnc2cc1OCc1nccn1C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.73
RET P07949 8/20 0.73
KIF5B P33176 6/20 0.73
BRAF P15056 2/20 0.58
EGFR P00533 8/20 0.57
RIPK2 O43353 2/20 0.57
NOD1 Q9Y239 2/20 0.57
JAK3 P52333 2/20 0.57
GAK O14976 1/20 0.57
STK10 O94804 1/20 0.57
FLT3 P36888 1/20 0.57
AAK1 Q2M2I8 1/20 0.57
Q6ZSR9 Q6ZSR9 1/20 0.57
SLK Q9H2G2 1/20 0.57
IRAK4 Q9NWZ3 1/20 0.57
RPS6KA6 Q9UK32 1/20 0.57
ALK Q9UM73 1/20 0.57
ERBB2 P04626 2/20 0.56
EPHA2 P29317 1/20 0.56
EPHB4 P54760 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7454698 0.99 KDR (0.71) KDRRETKIF5BBRAFEGFR
SCHEMBL8305714 0.89 EGFR (0.68) KDRRETKIF5BEGFRRIPK2
SCHEMBL5651286 0.85 KDR (1.00) KDRRETKIF5BBRAFEGFR
Hydrochloric Acid SCHEMBL7859467 0.84 KDR (0.98) KDRRETKIF5BBRAFEGFR
SCHEMBL8308738 0.84 KDR (0.66) KDRRETKIF5BEGFRGAK
SCHEMBL7455262 0.84 KDR (0.74) KDRRETKIF5BBRAFEGFR
Hydrochloric Acid SCHEMBL7458122 0.83 KDR (0.72) KDRRETKIF5BBRAFEGFR
SCHEMBL7454466 0.83 KDR (0.78) KDRRETKIF5BBRAFEGFR
SCHEMBL7455304 0.82 KDR (0.68) KDRRETKIF5BBRAFEGFR
Hydrochloric Acid SCHEMBL7455631 0.82 KDR (0.77) KDRRETKIF5BBRAFEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020032208-A1 Chemical compounds ZENECA LIMITED 2002-03-14 US claimed
EP-0873319-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-07-25 EP claimed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 US claimed
US-6362336-B1 ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT ZENECA LIMITED (GB) 2002-03-26 US disclosed
US-20020032208-A1 Chemical compounds ZENECA LIMITED 2002-03-14 US disclosed
US-6258951-B1 ANTICANCER, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 2001-07-10 US disclosed
US-6071921-A Chemical compounds ZENECA LIMITED (GB) 2000-06-06 US disclosed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032208-A1 Chemical compounds FLT1, CNKSR1, KDR KDR 3/4885RET 466/4885KIF5B 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.